Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
← catalyst calendarNCT05315700 · readout ≤ 42 d
Sponsored by ORIC Pharmaceuticals (industry) · ORIC — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
350estimated
Sites
42
Countries
Australia, Canada, Hong Kong +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-10 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-04-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumors
Interventions
- Drug: ORIC-114
- Drug: Chemotherapy drug — also filed as carboplatin and pemetrexed
Primary outcomes
what the primary-completion date above is the date OFRecommended Phase 2 Dose (RP2D)
measured 12 months
Maximum plasma concentration (Cmax)
measured 28 Days
Time of maximum observed concentration (Tmax)
measured 28 Days
Area under the curve (AUC)
measured 28 Days
Apparent plasma terminal elimination half-life (t1/2)
measured 28 Days
Permalink · ORIC's whole pipeline · Catalyst calendar · Every registered study · What changed